Zobrazeno 1 - 10
of 161
pro vyhledávání: '"Vasodilator drugs"'
Publikováno v:
The International Journal of Frontier Sciences, Vol 1, Iss 1 (2017)
Background: The operative treatment of cardiac diseases remains associated with systemic inflammation and a suboptimal outcome in many patients. These inflammatory changes are manifested by systemic hypotension, myocardial failure, increased vascular
Externí odkaz:
https://doaj.org/article/3bf8844e6db340d38a2a2cab341a8d6c
Publikováno v:
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J [Internet]. 2015;46(4):903–75.
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(Suppl):D42–D50.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;24;53(1):1.
Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med. 2017;141(5):696.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.
López Reyes R, Nauffal Manzur D, Garcia Ortega A, Menéndez Salinas MA, Ansotegui Barrera E, Balerdi Perez B. Clinical characteristics and survival of patients with pulmonary hypertension: a 40-month mean follow-up. Clin Respir J. 2017];11(1):103–12.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012; 142(2):448–56.
Scherrer U, Allemann Y, Rexhaj E, Rimoldi SF, Sartori C. Mechanisms and drug therapy of pulmonary hypertension at high altitude. High Alt Med Biol. 2013;14(2):126–33.
Gali N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31(17):2080–6.
Kemp K, Savale L, O’Callaghan DS, Jaís X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. J Hear Lung Transplant. 2012;31(2):150–8.
Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin V V., et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med [Internet]. 2015; 373(9):834–44.
Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314–22.
Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: The future is here. Eur Respir Rev. 2012;21(126):321–7.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–36.
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(Suppl):D51–D59.
Gerges C, Gerges M, Skoro-Sajer N, Zhou Y, Zhang L, Sadushi-Kolici R, Jakowitsch J, Lang MB, Lang IM, Hemodynamic thresholds for pre-capillary pulmonary hypertension, CHEST (2015), doi: 10.1378/chest.15-0928.
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2018; in press [https://doi.org/10.1183/13993003.01904-2018.
Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic characterization of EIF2AK4 mutation carrier in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 2017; 136: 2022–2033.
Rostagno C, Galanti G, Comeglio M, Boddi V, Olivo G, Gastone Neri Serneri G. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail. 2000 Sep;2(3):273-80.
Baba, M., Yoshida, K., & Ieda, M. Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. International Journal of Molecular Sciences. 2019; 20 (11), 2824. doi:10.3390/ijms20112824.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.
Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.
Curr Cardiovasc Risk Rep. 2021;15(1):2. doi: 10.1007/s12170-020-00663-3. Epub 2020 Nov 18.
Simonneau, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American journal of respiratory and critical care medicine. 2002; 165(6), 800–804.
Eur Respir J. 2014 Jun;43(6):1691-7. doi: 10.1183/09031936.00116313. Epub 2014 Mar 13.
Badagliacca, R., Pezzuto, B., Poscia, R., Mancone, M., Papa, S., Marcon, S., … Vizza, C. D. (2012). Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. The Journal of Heart and Lung Transplantation, 31(4), 364–372. doi:10.1016/j.healun.2011.12.011
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(Suppl):D42–D50.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;24;53(1):1.
Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med. 2017;141(5):696.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.
López Reyes R, Nauffal Manzur D, Garcia Ortega A, Menéndez Salinas MA, Ansotegui Barrera E, Balerdi Perez B. Clinical characteristics and survival of patients with pulmonary hypertension: a 40-month mean follow-up. Clin Respir J. 2017];11(1):103–12.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012; 142(2):448–56.
Scherrer U, Allemann Y, Rexhaj E, Rimoldi SF, Sartori C. Mechanisms and drug therapy of pulmonary hypertension at high altitude. High Alt Med Biol. 2013;14(2):126–33.
Gali N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31(17):2080–6.
Kemp K, Savale L, O’Callaghan DS, Jaís X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. J Hear Lung Transplant. 2012;31(2):150–8.
Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin V V., et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med [Internet]. 2015; 373(9):834–44.
Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314–22.
Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: The future is here. Eur Respir Rev. 2012;21(126):321–7.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–36.
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(Suppl):D51–D59.
Gerges C, Gerges M, Skoro-Sajer N, Zhou Y, Zhang L, Sadushi-Kolici R, Jakowitsch J, Lang MB, Lang IM, Hemodynamic thresholds for pre-capillary pulmonary hypertension, CHEST (2015), doi: 10.1378/chest.15-0928.
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2018; in press [https://doi.org/10.1183/13993003.01904-2018.
Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic characterization of EIF2AK4 mutation carrier in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 2017; 136: 2022–2033.
Rostagno C, Galanti G, Comeglio M, Boddi V, Olivo G, Gastone Neri Serneri G. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail. 2000 Sep;2(3):273-80.
Baba, M., Yoshida, K., & Ieda, M. Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. International Journal of Molecular Sciences. 2019; 20 (11), 2824. doi:10.3390/ijms20112824.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.
Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.
Curr Cardiovasc Risk Rep. 2021;15(1):2. doi: 10.1007/s12170-020-00663-3. Epub 2020 Nov 18.
Simonneau, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American journal of respiratory and critical care medicine. 2002; 165(6), 800–804.
Eur Respir J. 2014 Jun;43(6):1691-7. doi: 10.1183/09031936.00116313. Epub 2014 Mar 13.
Badagliacca, R., Pezzuto, B., Poscia, R., Mancone, M., Papa, S., Marcon, S., … Vizza, C. D. (2012). Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. The Journal of Heart and Lung Transplantation, 31(4), 364–372. doi:10.1016/j.healun.2011.12.011
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: El tratamiento de la hipertensión pulmonar arterial es un reto clínico, ya que requiere una estrategia compleja y multidisciplinaria, fundamentada en el uso de vasodilatadores pulmonares. Las investigaciones actuales se enfocan princ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85cbf8a483b7b09d730b237df5a21cbf
https://repository.urosario.edu.co/handle/10336/32223
https://repository.urosario.edu.co/handle/10336/32223
Oral vasodilator therapy remains the cornerstone of treatment for heart failure in the young, but the evidence base is limited. The vast majority of clinical trials (as well as many physiological and pathological studies) in heart failure have taken
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::238d87e33970e6dd2014474dacc0ee40
https://doi.org/10.1016/b978-0-12-802393-8.00041-7
https://doi.org/10.1016/b978-0-12-802393-8.00041-7
Publikováno v:
Principles of Nuclear Medicine ISBN: 9783319917009
1. All drugs may enhance uptake by altering the biokinetics of the radiopharmaceutical EXCEPT: (a) β-Adrenergic blocking agents (b) Vasodilator drugs (c) Calcium channel-blocking drugs (d) Sympathomimetic agents 2. Which radionuclide does NOT emit a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::188b36860ba8be73beb5062314e9f38d
https://doi.org/10.1007/978-3-319-91701-6_2
https://doi.org/10.1007/978-3-319-91701-6_2
Autor:
Mamas A. Mamas, Magdi El-Omar
Publikováno v:
EuroIntervention. 9:169-172
For an iFR of 0.93, they recommend deferring treatment and for the intermediate range of iFRs (0.86-0.93), they recommend proceeding to FFR. By pursuing such hybrid strategy, the need for vasodilator drugs (and thus FFR) is obviated in 57% of cases,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8048691df00bd5972c15760b2cfc6ba6
https://doi.org/10.4244/eijv9i1a26
https://doi.org/10.4244/eijv9i1a26
Autor:
Roberto Soares de Moura, Celso Luiz Salgueiro Lage, Cristiane Pimentel Victório, Ricardo Machado Kuster
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences; Vol. 45 No. 3 (2009); 507-514
Brazilian Journal of Pharmaceutical Sciences; Vol. 45 Núm. 3 (2009); 507-514
Brazilian Journal of Pharmaceutical Sciences; v. 45 n. 3 (2009); 507-514
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Brazilian Journal of Pharmaceutical Sciences, Vol 45, Iss 3, Pp 507-514 (2009)
Brazilian Journal of Pharmaceutical Sciences, Volume: 45, Issue: 3, Pages: 507-514, Published: SEP 2009
Brazilian Journal of Pharmaceutical Sciences; Vol. 45 Núm. 3 (2009); 507-514
Brazilian Journal of Pharmaceutical Sciences; v. 45 n. 3 (2009); 507-514
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Brazilian Journal of Pharmaceutical Sciences, Vol 45, Iss 3, Pp 507-514 (2009)
Brazilian Journal of Pharmaceutical Sciences, Volume: 45, Issue: 3, Pages: 507-514, Published: SEP 2009
Nowadays, the high blood pressure is one of the main causes of death and cardiovascular diseases. Vasodilator drugs are frequently used to treat arterial hypertension. Experiments were undertaken to determine whether hydroalcoholic extracts obtained
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::589f650871c182b7e89db6325b36ccd8
https://doi.org/10.1590/s1984-82502009000300017
https://doi.org/10.1590/s1984-82502009000300017
Autor:
C. Salazar Ramírez, C. Fernández Aguirre, F. Cota Delgado, J. L. Velasco Garrido, D. Daga Ruiz, M. V. Hidalgo Sanjuán
Publikováno v:
Medicina Intensiva v.34 n.9 2010
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
La hipertensión pulmonar es una patología grave con un tratamiento complejo basado en medidas generales, anticoagulación y utilización de fármacos específicos vasodilatadores. La insuficiencia cardiaca derecha instaurada en estadios finales de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d05489d7d8846c87a62516bcfd00ef6
https://doi.org/10.1016/j.medin.2009.12.006
https://doi.org/10.1016/j.medin.2009.12.006
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
K.S. Bhullar, H.P.V. Rupasinghe
Publikováno v:
Artery Research, Vol 5, Iss 4 (2011)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::746d0d7b56496ed07ce2ae59cc0b4c61
https://www.atlantis-press.com/article/125927931/view
https://www.atlantis-press.com/article/125927931/view